FDA CDER Updates
The latest guidances, approvals, and safety alerts from FDA CDER, curated by automated regulatory intelligence.
Clarifies how sponsors should evaluate and document QT/QTc interval prolongation and proarrhythmic risk during both clinical studies and nonclinical…
Clarifies how to submit clinical trial data intended to support the ability to operate a motor vehicle, including expectations for generating and presenting…
Clarifies how FDA expects firms to assess and manage risks when prescription drug use-related software is introduced into clinical care workflows, with an…
Clarifies and standardizes safety reporting obligations for IND sponsors and for sponsors conducting BA/BE studies, aiming to ensure timely submission of…
Clarifies how FDA expects sponsors of biosimilar and interchangeable biosimilar products to manage and document postapproval manufacturing changes, including…
Clarifies how FDA expects sponsors to develop, evaluate, and submit biosimilar applications under the BPCI Act, with emphasis on demonstrating…
Provides FDA/CDER technical conformance expectations for study data submissions, guiding sponsors on how to structure and format data to support regulatory…
Establishes standardized E2B(R3) electronic transmission requirements for individual case safety reports (ICSRs), including detailed data elements and message…
Establishes temporary FDA policy for compounding certain starter parenteral nutrition products intended for neonates, aiming to maintain supply while…
Clarifies how pharmacokinetic (PK) studies should be designed and analyzed to evaluate drug exposure in patients with impaired hepatic function, with the goal…
Clarifies how pharmacokinetic studies in patients with impaired hepatic function should be designed and analyzed to support labeling recommendations, with an…
Clarifies FDA expectations for demonstrating therapeutic equivalence for approved drug products, with emphasis on the evidentiary basis used to support…
Clarifies the decision logic and evidentiary expectations for applicants determining whether a generic drug should be filed as an ANDA or supported via a…
Provides draft FDA recommendations on the design, qualification, and control of container closure systems (CCS) for human drugs and biological products…
Clarifies how FDA will conduct and manage formal meetings with sponsors/applicants for PDUFA-related products, including expectations for requests, agenda, and…
Topic: Status: Draft.
Topic: Status: Final.
Topic: Status: Draft.
Outlines FDA’s key considerations for designing, conducting, and monitoring clinical investigations involving psychedelic drugs, with an emphasis on patient…
Clarifies FDA expectations for demonstrating in vivo bioequivalence for topical dermatologic corticosteroid products, which may affect study design, bridging…